Tradipitant in the Treatment of Gastroparesis: Vanda Presents Clinical Trial Results at DDW 2019

WASHINGTON , May 22, 2019 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (VANDA) (Nasdaq: VNDA) today announced the results of the Phase II study of tradipitant in gastroparesis were presented at Digestive Disease Week ® (DDW) 2019 in San Diego , CA. For more information on DDW 2019, please refer to https://ddw.org/home . About Vanda Vanda is a global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. For more on Vanda Pharmaceuticals Inc. , please visit www.vandapharma.com . Investor Contact: Jim Kelly Executive Vice President & Chief Financial Officer Vanda Pharmaceuticals Inc. (202) 734-3428 [email protected] Media Contacts: AJ Jones II Burson Cohn & Wolfe (BCW) 1110 Vermont Avenue, NW , Suite 1200 Washington, D.C. 20005 202-530-0400 [email protected] Elizabeth Van Every Burson Cohn & Wolfe (BCW) 230 Park Avenue South New York, NY 10003 212-614-3881 [email protected] View original content: http://www.prnewswire.com/news-releases/tradipitant-in-the-treatment-of-gastroparesis-vanda-presents-clinical-trial-results-at-ddw-2019-300855295.html SOURCE Vanda Pharmaceuticals Inc. Investor Relations IR Home Stock Information Stock Quote Stock Chart SEC Filings Analyst Coverage Corporate Governance Highlights Management Board of Directors Committee Composition Guidelines VandaHotline Information Request E-mail Alerts Tools Print Page E-mail Page Home About Vanda Product Pipeline Partnering investor Relations News Careers Contact Us Copyright © 2005-2026 Vanda Pharmaceuticals Inc. | Live - Terms & Policy Terms & Conditions | Privacy Policy

The release as fetched from its publisher. vandapharma.com ↗